Life Sciences and Healthcare in focus

Life Sciences and Healthcare

Industries making an impact on modern society

Life sciences, health and social care are vitally important in the development of modern society, with a diverse range of stakeholders, from the general public and clinical practitioners to regulators, insurers and governments. We understand the unique challenges of the industry and deliver results-focused advice for a diverse range of clients, from drug developers to healthcare providers and the entities that finance and support them.

Our focus areas

Biotech and pharmaceuticals

In life sciences, we have a strong track record in domestic and cross-border mergers and acquisitions, helping our clients to monetise their assets through creative partnering with early-stage entrepreneurial and established companies, and by providing IP and tax advice.

Learn more

Digital health

Our specialist healthcare technology practice advises the companies and investors that are transforming the way therapies and patient services are delivered.

Learn more


In health and social care, we advise on everything from the building and operating of hospitals and care homes to the provision of new methods of diagnosis and treatment.

Learn more


Bone Therapeutics

Advised Bone Therapeutics, addressing high unmet medical needs in orthopaedics and bone diseases, on its €16 million loan financing from the European Investment Bank to support and prepare their lead asset, enhanced viscosupplement JTA-004, for future regulatory approval and commercialisation. Read more here >

NeRRe Therapeutics

Advised NeRRe Therapeutics on its £20 million Series B2 financing round. The financing involved a syndicate of leading transatlantic life sciences investors led by new investor Columbus Venture Partners and existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed. Read more here >


Advised global healthcare leader, Grifols on a ~USD 1 billion strategic investment from Singapore’s sovereign wealth fund. Read more here >

firstminute capital

Osborne Clarke advises firstminute capital on investment in Vantis, read more

Amphista Therapeutics

Advised Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, on its $53 million (£38 million) Series B financing round. Read more.


Advised Grifols on its strategic alliance and investment in Shanghai RAAS.


Advised long-standing client LDC together with the management team on the sale of Penn Pharma in a transaction worth £127m.


Advised on a series A investment in Belgian biotech company Univercells.

Telefonica Alpha

Advised Telefonica Alpha (Barcelona) on a software service and the applicability of both healthcare and medical device regulation.

UK telco

Advised a UK telco on regulatory compliance for a range of proposed 'mhealth' services, including whether the services were healthcare services and/or used medical devices.

Healthcare provider

Advised a digital primary care healthcare provider on EU and UK health and data regulations, preparing global contracting documentation and insurance advice.

Intrapharm Laboratories Ltd

Advised Intrapharm Laboratories Ltd management team and all of its shareholders on the disposal of the company to German pharmaceutical company RIEMSER Pharma GmbH.

Drug discovery company

Advised the shareholders of a privately held drug discovery company on its acquisition by C4X Discovery Holdings plc in exchange for shares in C4X.

Roche Diagnostics GmbH

Advised Roche Diagnostics GmbH on the revision of their privacy policy and end-user licence agreements.

Roche Diagnostics GmbH

Advised Roche Diagnostics GmbH on a cloud-based solution for securely hosting critical medical data in compliance with data protection laws in over 30 countries.

Imperial Innovations Group plc

Advised Imperial Innovations Group plc and SV Life Sciences on a £19 million series A investment in Kesios Therapeutics.

First Water

Advised the shareholders of First Water on its acquisition by Scapa Group for consideration of up to £15.3m payable depending on performance in 2016, 2017 and 2018.

Sirigen Group Ltd

Advised medical technology Sirigen Group Ltd on its acquisition by Becton, Dickinson and Company, a leading global medical technology company, for an undisclosed sum.

Takeda Ventures

Advised Takeda Ventures, Inc and Takeda Pharmaceuticals on the investment and formation of a drug discovery collaboration with Heptares Therapeutics Ltd.


Fact #20

We advised Grifols on its €5bn acquisition of US company Talecris

Life Sciences and Healthcare


View all insights

Connect with one of our experts

Silvia Steiner's Profile Image

Find your local Life Sciences and Healthcare experts